Technical analysis of Nyxoah S.A. (NYXH): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Price Performance
| 1 month | -6.06% |
| 3 months | -3.13% |
| Year-to-date | -66.30% |
| 1 year | -67.57% |
| 3 years | -80.50% |
52-Week Range
| 52-week High | $6.87 |
| 52-week Low | $1.26 |
| Avg Volume (90d) | 354K |
Technical Indicators
| SMA 50 | $1.55 |
| SMA 200 | $3.08 |
| Beta | 0.87 |
| 30-day Volatility (annualised) | 75.6% |
| Price vs SMA 50 | -0.1% |
| Price vs SMA 200 | -49.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $5.19 | |
| 2025-11 | $4.80 | -7.5% |
| 2025-12 | $4.60 | -4.2% |
| 2026-01 | $4.75 | +3.3% |
| 2026-02 | $4.08 | -14.1% |
| 2026-03 | $2.92 | -28.4% |
| 2026-04 | $2.95 | +1.0% |
| 2026-05 | $2.98 | +1.0% |
| 2026-06 | $1.69 | -43.3% |
| 2026-07 | $1.40 | -17.2% |
| 2026-08 | $1.56 | +11.4% |
| 2026-09 | $1.55 | -0.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | $-0.00 | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $1.49 |
| Market Cap | $149M |
| Exchange | NASDAQ |
| Country | BE |
Valuation Ratios
| Price / Book | 0.88 |
| EV / EBITDA | -1.59 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.63 |
| Current Ratio | 2.38 |